Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
about
P108
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult ParticipantsA Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionA Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory InfectionsA Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideA Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult ParticipantsA Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different FacilitiesA Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female ParticipantsA Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy ParticipantsAn Efficacy and Safety Study of Golimumab in Participants With Ulcerative ColitisAn Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisOpen-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF AgentsA Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy VolunteersA Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy VolunteersA Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple MyelomaA Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy VolunteersA Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy VolunteersEffect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy VolunteersA Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male VolunteersA Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes MellitusA Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionA Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusA Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaA Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/LymphomaA Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With FoodA Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly ParticipantsStudy to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus InfectionA Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy ParticipantsA Study of Guselkumab in Participants With Familial Adenomatous PolyposisA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerA Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy ParticipantsA Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisStudy of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple MyelomaA Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese ParticipantsA Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse EventsFluoroquinolone Associated DisabilityA Study of Ustekinumab in Participants With Active Systemic Lupus ErythematosusA Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
P859
Q61729716-63477A44-E9D7-4CF1-BF96-1263A1B2CC5DQ61862274-CBF64A8E-7FFB-40A4-B3F6-5F1A5CFD101CQ61894191-79E8A08E-4DA6-44DE-8A8A-62569BA939F1Q61894198-6F91B4C3-0024-4C16-84E4-FB8165BFBFCFQ61894500-744D29A1-4016-4729-8D02-BC0EBE1408ABQ61894623-2E41C5A9-05AA-4C30-9082-4711F912B911Q61907128-A50A4D33-92D2-43DB-823F-B5816E093AC8Q61909627-04D7372F-82B2-4B5A-B5F7-222D5E9E5C25Q61918205-A501F70C-7B13-4018-B952-26C09F13993BQ61918221-B955C4F4-7E5F-445D-A32A-57F246358EB8Q61918250-62E5A758-BB96-49E3-B472-1D9DF637F5E9Q61938037-9FD0E5FA-4C06-470A-97AF-54C1D4443D2CQ61956616-02C7A423-6E56-49C1-834E-EAABB6A8CDC7Q61956618-454CCA3C-50FD-4C04-A1FA-0D714B5CF4DDQ61956801-C79B404E-14A8-497C-B664-DB08E4D95EE1Q61956857-6EF876CA-8A27-4551-B063-33326379112EQ61956949-BE789B36-9DE8-4705-A10D-B19AB08CE29BQ61965816-0A45F008-2BDF-4DAC-8C39-92915A0E5882Q61966637-0A1F97E5-F42C-460C-A3C2-EA6B6BB99401Q61969270-77A6AECC-6ACD-4162-A698-CB5627670281Q61969405-361C1596-EC8A-40C9-AD2A-E66F62D517C2Q61970149-CD175C7E-F42F-42DB-B0EF-E09B39F85B47Q61975040-C99D8327-EF60-4510-989B-DA458C03DECDQ61975124-AB055A16-F81A-4EE1-8836-B831ECB3E94BQ61975388-71CA26D6-A9C5-4F08-9DF7-2A7E76D442A0Q61975448-F7C4F64F-EE3C-414C-887F-5E16CC27CD79Q61975663-81C70BAC-7123-4B7E-86D8-9AC87C60D03EQ61975826-518CDDBD-319A-463C-ADA9-BFD5B7058146Q62024887-54906DCC-5D37-4267-B71A-8535726CD89FQ62025456-E8223657-68D5-40C5-B564-F2E2E2E395E5Q62025459-759791A2-FE24-4AF7-A4F1-FCCFC4B29155Q62034171-B7E6A0C4-35D2-4620-875A-048945E416CEQ62054824-44D16E02-F593-4C9F-9418-5FEB79111054Q62062226-F30AB252-23BA-4B3A-B28D-C82988FB0231Q62105998-80C30B30-DEF0-496F-8D16-AE909A61E0F7Q62809298-DCC00307-CFBC-43D5-B7D4-5011C18ECE71Q62811718-85B69928-D197-49E4-B67D-7D5114897F10Q62814462-F3462BDA-6909-460D-9FC0-981EFE1A0256Q62817347-26120B4C-C63E-4E6D-9017-AE7EF704ABC3Q63011504-EA6B5556-16FD-4011-B2CF-DD831E8FB337
P859
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
description
Organisation
@de
organisaatio
@fi
organization
@en
organizatë
@sq
name
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
@en
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
@fr
type
label
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
@en
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
@fr
prefLabel
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
@en
Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.
@fr